Neoplastic meningitis
disease diseaseOn this page
Also known as carcinomatous meningitisleptomeningeal carcinomaleptomeningeal carcinomatosisleptomeningeal metastasismeningeal carcinomatosismeningeal metastasismetastatic malignant neoplasm in the leptomeninges
Summary
Neoplastic meningitis (MONDO:0700219) is a disease and 87 clinical trials. Top therapeutic interventions include methotrexate, osimertinib, and lorlatinib. A subtype of metastatic malignant neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 87
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | neoplastic meningitis |
| Mondo ID | MONDO:0700219 |
| ICD-11 | 262966673 |
| NCIT | C27383, C3814 |
| UMLS | C1704231 |
| MedGen | 352817 |
| Is cancer (heuristic) | no |
Also known as: carcinomatous meningitis · leptomeningeal carcinoma · leptomeningeal carcinomatosis · leptomeningeal metastasis · meningeal carcinomatosis · meningeal metastasis · metastatic malignant neoplasm in the leptomeninges
Disease family
This is a subtype of metastatic malignant neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › secondary malignant neoplasm › metastatic malignant neoplasm › neoplastic meningitis
Related subtypes (6): metastatic carcinoma, metastatic malignant neoplasm in the colon, metastasis from malignant tumor of colon, metastatic malignant neoplasm in the spinal cord, metastatic malignant neoplasm in the eye, metastatic malignant neoplasm in the brain
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 87.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 29 |
| PHASE2 | 23 |
| PHASE1 | 16 |
| PHASE1/PHASE2 | 11 |
| PHASE4 | 6 |
| PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06230055 | PHASE4 | RECRUITING | Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis |
| NCT06282874 | PHASE4 | ACTIVE_NOT_RECRUITING | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases |
| NCT07092202 | PHASE4 | RECRUITING | Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases |
| NCT02590510 | PHASE4 | UNKNOWN | Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis |
| NCT04356118 | PHASE4 | UNKNOWN | Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis |
| NCT04356222 | PHASE4 | UNKNOWN | Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis |
| NCT06500481 | PHASE3 | RECRUITING | Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial |
| NCT03613181 | PHASE3 | UNKNOWN | ANG1005 in Leptomeningeal Disease From Breast Cancer |
| NCT04588545 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease |
| NCT05800275 | PHASE2 | RECRUITING | Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease |
| NCT05805631 | PHASE2 | RECRUITING | Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC |
| NCT06058988 | PHASE2 | RECRUITING | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer |
| NCT06296745 | PHASE2 | RECRUITING | Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. |
| NCT06441045 | PHASE2 | NOT_YET_RECRUITING | Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI |
| NCT06462222 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors |
| NCT06518057 | PHASE2 | RECRUITING | Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer |
| NCT06762080 | PHASE1/PHASE2 | RECRUITING | Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis |
| NCT06809517 | PHASE1/PHASE2 | RECRUITING | Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis |
| NCT06809530 | PHASE1/PHASE2 | RECRUITING | Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis |
| NCT06901817 | PHASE2 | RECRUITING | A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases |
| NCT06910761 | PHASE2 | RECRUITING | Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer |
| NCT07177950 | PHASE1/PHASE2 | NOT_YET_RECRUITING | A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases |
| NCT07264569 | PHASE1/PHASE2 | RECRUITING | Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 |
| NCT07551414 | PHASE2 | NOT_YET_RECRUITING | Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI |
| NCT00523939 | PHASE2 | TERMINATED | DepoCyt for Active Lymphomatous or Leukemic Meningitis |
| NCT00830245 | PHASE2 | TERMINATED | A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer |
| NCT00924820 | PHASE1/PHASE2 | COMPLETED | A Pilot Study of Bevacizumab for Neoplastic Meningitis |
| NCT01281696 | PHASE2 | COMPLETED | Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis |
| NCT01373710 | PHASE1/PHASE2 | COMPLETED | Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis |
| NCT01818713 | PHASE2 | UNKNOWN | Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases |
| NCT02939300 | PHASE2 | COMPLETED | Ipilimumab and Nivolumab in Leptomeningeal Metastases |
| NCT03082144 | PHASE2 | COMPLETED | Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid Tumors |
| NCT03507244 | PHASE1/PHASE2 | COMPLETED | Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors |
| NCT04148898 | PHASE2 | UNKNOWN | Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis |
| NCT04233021 | PHASE2 | COMPLETED | Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation |
| NCT04315246 | PHASE1/PHASE2 | WITHDRAWN | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) |
| NCT04420598 | PHASE2 | COMPLETED | DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease |
| NCT04425681 | PHASE2 | UNKNOWN | Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer |
| NCT04729348 | PHASE2 | TERMINATED | Pembrolizumab And Lenvatinib In Leptomeningeal Metastases |
| NCT04833205 | PHASE2 | UNKNOWN | Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| METHOTREXATE | 4 | 4 |
| OSIMERTINIB | 4 | 3 |
| LORLATINIB | 4 | 2 |
| TRASTUZUMAB DERUXTECAN | 4 | 2 |
| DURVALUMAB | 4 | 1 |
| TUCATINIB | 4 | 1 |
| FIRMONERTINIB | 3 | 3 |
| ANG1005 | 3 | 2 |
| AUMOLERTINIB | 3 | 2 |
| AZELIRAGON | 3 | 1 |
| IVONESCIMAB | 3 | 1 |
| NIMOTUZUMAB | 3 | 1 |
| BERUBICIN HYDROCHLORIDE | 2 | 2 |
| ADAVOSERTIB | 2 | 1 |
| PAXALISIB | 2 | 1 |
| RHENIUM RE-186 OBISBEMEDA | 1 | 2 |
| TROTABRESIB | 1 | 1 |
| CHEMBL4303155 | 0 | 2 |
| CHEMBL4436406 | 0 | 2 |
| CHEMBL5289235 | 0 | 2 |
| CHEMBL426 | 0 | 1 |